NovelMed Therapeutics
Our Promise to PatientsBacked by robust intellectual property and promising Phase II results (NovelMed’s Phase II Data in PNH Patients), Ruxoprubart (NM8074) is well-positioned to capture a significant share of the rare disease market. Supported by strong data from preclinical, pharmacological, toxicological, and clinical studies, NovelMed is on track to deliver transformative therapies for patients with unmet needs.
Private Company
Total funding raised: $25M
About
Our Promise to PatientsBacked by robust intellectual property and promising Phase II results (NovelMed’s Phase II Data in PNH Patients), Ruxoprubart (NM8074) is well-positioned to capture a significant share of the rare disease market. Supported by strong data from preclinical, pharmacological, toxicological, and clinical studies, NovelMed is on track to deliver transformative therapies for patients with unmet needs.